drug
brensocatib
Marketedupdated 3mo agoby $INSM INSMED Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying brensocatib
- phase2A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
- phase2A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
- phase3A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
- phase2A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
- —An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis
- phase1A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
- phase1A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
- phase1A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 12, 2030
~4.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (28)
- Feb 21, 2040formulationUS 12059424
- Feb 21, 2040formulationUS 12059424
- Mar 1, 2039formulationUS 12201638
- Mar 1, 2039formulationUS 12201638
- Mar 12, 2035compositionUS 9522894
- Mar 12, 2035compositionUS 9522894
- Jan 21, 2035compositionUS 10287258
- Jan 21, 2035compositionUS 10287258
- Jan 21, 2035compositionUS 10669245
- Jan 21, 2035compositionUS 10669245
- Jan 21, 2035formulationUS 11655221
- Jan 21, 2035formulationUS 11655221
- Jan 21, 2035compositionUS 11655222
- Jan 21, 2035compositionUS 11655222
- Jan 21, 2035compositionUS 11655223
- Jan 21, 2035compositionUS 11655223
- Jan 21, 2035formulationUS 11655224
- Jan 21, 2035formulationUS 11655224
- Jan 21, 2035formulationUS 11673871
- Jan 21, 2035formulationUS 11673871
- Jan 21, 2035formulationUS 11773069
- Jan 21, 2035formulationUS 11773069
- Jan 21, 2035compositionUS 11814359
- Jan 21, 2035compositionUS 11814359
- Jan 21, 2035compositionUS 12054465
- Jan 21, 2035compositionUS 12054465
- Jan 21, 2035method-of-use (U-4257)US 9815805
- Jan 21, 2035method-of-use (U-4257)US 9815805
FDA exclusivities (2)
- Aug 12, 2030NCENew Chemical Entity (5y)4.0y
- Aug 12, 2030NCENew Chemical Entity (5y)4.0y
News(4)
- Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce has learned.fiercebiotech · 7d ago
- A COPD drug from China draws $115M in venture fundingExpedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.biopharma_dive · 7d ago
- Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journeyExpedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.fiercebiotech · 8d ago
- Insmed moves closer to $6B opportunity as PAH drug shows long-term durabilityInsmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements thro…biospace · 26d ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that